SA06260465B1 - أملاح ناتجة عن إضافة أحماض من بيبريدينيل (4) أميد لحمض 4-(2، 6-ثنائـي كلـورو-بنزويـل أمينـو)-1h-بيـرازول-3-كربوكسيليـك - Google Patents

Info

Publication number

SA06260465B1

SA06260465B1 SA6260465A SA06260465A SA06260465B1 SA 06260465 B1 SA06260465 B1 SA 06260465B1 SA 6260465 A SA6260465 A SA 6260465A SA 06260465 A SA06260465 A SA 06260465A SA 06260465 B1 SA06260465 B1 SA 06260465B1

Authority

SA

Saudi Arabia

Prior art keywords

pyrazole

salt

acid

benzoylamino

dichloro

Prior art date

2005-01-21

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003839 salts Chemical class 0.000 title claims abstract description 376
• 239000002253 acid Substances 0.000 title claims abstract description 271
• OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 title claims description 22
• 150000001408 amides Chemical class 0.000 claims abstract description 174
• 238000000034 method Methods 0.000 claims abstract description 143
• 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 135
• 239000000203 mixture Substances 0.000 claims abstract description 133
• -1 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid 4-(2,6-Dichloro-benzoylamino)-1H -pyrazole-3-carboxylic acid piperidin-4-ylamide Chemical compound 0.000 claims abstract description 110
• BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims abstract description 86
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 77
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 75
• 239000013078 crystal Substances 0.000 claims abstract description 64
• 230000008569 process Effects 0.000 claims abstract description 44
• 239000000126 substance Substances 0.000 claims abstract description 35
• BRZQYVXJAZMSBB-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl BRZQYVXJAZMSBB-UHFFFAOYSA-N 0.000 claims abstract description 29
• 238000002360 preparation method Methods 0.000 claims abstract description 17
• 239000000543 intermediate Substances 0.000 claims abstract description 15
• 150000001875 compounds Chemical class 0.000 claims description 170
• 239000000243 solution Substances 0.000 claims description 113
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
• 238000011282 treatment Methods 0.000 claims description 79
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 73
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 71
• 206010028980 Neoplasm Diseases 0.000 claims description 68
• 102000016736 Cyclin Human genes 0.000 claims description 67
• 108050006400 Cyclin Proteins 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 67
• 230000000694 effects Effects 0.000 claims description 50
• 239000002904 solvent Substances 0.000 claims description 43
• 239000003814 drug Substances 0.000 claims description 40
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 38
• 201000011510 cancer Diseases 0.000 claims description 38
• 239000000843 powder Substances 0.000 claims description 37
• 210000004027 cell Anatomy 0.000 claims description 36
• 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 31
• 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 31
• 108091000080 Phosphotransferase Proteins 0.000 claims description 31
• 102000020233 phosphotransferase Human genes 0.000 claims description 31
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 28
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 28
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
• 239000000047 product Substances 0.000 claims description 27
• 206010025323 Lymphomas Diseases 0.000 claims description 26
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 26
• 239000008194 pharmaceutical composition Substances 0.000 claims description 25
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 24
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 24
• 239000012458 free base Substances 0.000 claims description 24
• 238000006243 chemical reaction Methods 0.000 claims description 23
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 23
• 239000007864 aqueous solution Substances 0.000 claims description 22
• 229940079593 drug Drugs 0.000 claims description 22
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 22
• 238000002441 X-ray diffraction Methods 0.000 claims description 21
• 125000006239 protecting group Chemical group 0.000 claims description 20
• 230000002401 inhibitory effect Effects 0.000 claims description 19
• WUYZRUOVGJFWLD-UHFFFAOYSA-N n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound C=1C=NNC=1C(=O)NC1CCNCC1 WUYZRUOVGJFWLD-UHFFFAOYSA-N 0.000 claims description 19
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 18
• 230000002159 abnormal effect Effects 0.000 claims description 18
• 239000001257 hydrogen Substances 0.000 claims description 18
• 229910052739 hydrogen Inorganic materials 0.000 claims description 18
• 239000003960 organic solvent Substances 0.000 claims description 18
• 239000007853 buffer solution Substances 0.000 claims description 17
• 238000010438 heat treatment Methods 0.000 claims description 16
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
• 239000002585 base Substances 0.000 claims description 15
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 15
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 13
• 229920002527 Glycogen Polymers 0.000 claims description 13
• 229940096919 glycogen Drugs 0.000 claims description 13
• 208000026310 Breast neoplasm Diseases 0.000 claims description 12
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
• 230000010261 cell growth Effects 0.000 claims description 12
• 238000000113 differential scanning calorimetry Methods 0.000 claims description 12
• 230000012010 growth Effects 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 12
• 230000004224 protection Effects 0.000 claims description 12
• 206010006187 Breast cancer Diseases 0.000 claims description 11
• 238000002425 crystallisation Methods 0.000 claims description 11
• 230000008025 crystallization Effects 0.000 claims description 11
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 10
• 230000001419 dependent effect Effects 0.000 claims description 10
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
• 239000002244 precipitate Substances 0.000 claims description 10
• 230000002265 prevention Effects 0.000 claims description 10
• 230000001681 protective effect Effects 0.000 claims description 10
• 238000001953 recrystallisation Methods 0.000 claims description 10
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
• 208000032839 leukemia Diseases 0.000 claims description 9
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
• 108091007911 GSKs Proteins 0.000 claims description 8
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
• 230000001575 pathological effect Effects 0.000 claims description 8
• 108010001483 Glycogen Synthase Proteins 0.000 claims description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 7
• 230000001684 chronic effect Effects 0.000 claims description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
• KOPFEFZSAMLEHK-UHFFFAOYSA-N 1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1C=CNN=1 KOPFEFZSAMLEHK-UHFFFAOYSA-N 0.000 claims description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 6
• 125000004429 atom Chemical group 0.000 claims description 6
• 210000000481 breast Anatomy 0.000 claims description 6
• 230000008859 change Effects 0.000 claims description 6
• 125000004122 cyclic group Chemical group 0.000 claims description 6
• 230000001965 increasing effect Effects 0.000 claims description 6
• 238000002329 infrared spectrum Methods 0.000 claims description 6
• 230000002452 interceptive effect Effects 0.000 claims description 6
• 210000004072 lung Anatomy 0.000 claims description 6
• 150000001242 acetic acid derivatives Chemical class 0.000 claims description 5
• 239000000872 buffer Substances 0.000 claims description 5
• 230000033077 cellular process Effects 0.000 claims description 5
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 210000001072 colon Anatomy 0.000 claims description 5
• 238000011321 prophylaxis Methods 0.000 claims description 5
• 125000001424 substituent group Chemical group 0.000 claims description 5
• 150000001204 N-oxides Chemical class 0.000 claims description 4
• 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 4
• 230000032823 cell division Effects 0.000 claims description 4
• 208000024207 chronic leukemia Diseases 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 150000007524 organic acids Chemical class 0.000 claims description 4
• 239000012266 salt solution Substances 0.000 claims description 4
• 210000002784 stomach Anatomy 0.000 claims description 4
• 210000001685 thyroid gland Anatomy 0.000 claims description 4
• QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 claims description 3
• 201000009030 Carcinoma Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 101150073031 cdk2 gene Proteins 0.000 claims description 3
• 238000011161 development Methods 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000003325 follicular Effects 0.000 claims description 3
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 3
• 125000000623 heterocyclic group Chemical group 0.000 claims description 3
• 201000001441 melanoma Diseases 0.000 claims description 3
• 150000007522 mineralic acids Chemical class 0.000 claims description 3
• IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 3
• 210000000496 pancreas Anatomy 0.000 claims description 3
• 210000002307 prostate Anatomy 0.000 claims description 3
• 239000012453 solvate Substances 0.000 claims description 3
• 238000001228 spectrum Methods 0.000 claims description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
• HBZVNWNSRNTWPS-UHFFFAOYSA-N 6-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(O)C2=CC(N)=CC=C21 HBZVNWNSRNTWPS-UHFFFAOYSA-N 0.000 claims description 2
• 244000198134 Agave sisalana Species 0.000 claims description 2
• 240000005702 Galium aparine Species 0.000 claims description 2
• 235000014820 Galium aparine Nutrition 0.000 claims description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
• CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 201000010208 Seminoma Diseases 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 235000010443 alginic acid Nutrition 0.000 claims description 2
• 229920000615 alginic acid Polymers 0.000 claims description 2
• 150000004781 alginic acids Chemical class 0.000 claims description 2
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
• 210000003679 cervix uteri Anatomy 0.000 claims description 2
• 239000006184 cosolvent Substances 0.000 claims description 2
• 210000003238 esophagus Anatomy 0.000 claims description 2
• 210000000232 gallbladder Anatomy 0.000 claims description 2
• 210000003734 kidney Anatomy 0.000 claims description 2
• 210000004185 liver Anatomy 0.000 claims description 2
• 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
• 201000008968 osteosarcoma Diseases 0.000 claims description 2
• 210000001672 ovary Anatomy 0.000 claims description 2
• 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
• 238000012545 processing Methods 0.000 claims description 2
• 230000001012 protector Effects 0.000 claims description 2
• 238000000926 separation method Methods 0.000 claims description 2
• 239000011734 sodium Substances 0.000 claims description 2
• 229910052708 sodium Inorganic materials 0.000 claims description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
• 125000003545 alkoxy group Chemical group 0.000 claims 6
• 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
• 229910052736 halogen Inorganic materials 0.000 claims 4
• 229910052731 fluorine Inorganic materials 0.000 claims 3
• 239000011737 fluorine Substances 0.000 claims 3
• 150000002367 halogens Chemical class 0.000 claims 3
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 2
• 206010033128 Ovarian cancer Diseases 0.000 claims 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
• 208000001608 teratocarcinoma Diseases 0.000 claims 2
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
• 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
• 101100223811 Caenorhabditis elegans dsc-1 gene Proteins 0.000 claims 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 1
• 206010013786 Dry skin Diseases 0.000 claims 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
• 101710102502 Glycogen synthase kinase 1 Proteins 0.000 claims 1
• 206010025280 Lymphocytosis Diseases 0.000 claims 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
• 240000002390 Pandanus odoratissimus Species 0.000 claims 1
• 235000005311 Pandanus odoratissimus Nutrition 0.000 claims 1
• 206010048218 Xeroderma Diseases 0.000 claims 1
• 125000002947 alkylene group Chemical group 0.000 claims 1
• 125000004432 carbon atom Chemical group C* 0.000 claims 1
• 150000005676 cyclic carbonates Chemical group 0.000 claims 1
• 230000037336 dry skin Effects 0.000 claims 1
• 201000004101 esophageal cancer Diseases 0.000 claims 1
• 150000002431 hydrogen Chemical class 0.000 claims 1
• 206010021198 ichthyosis Diseases 0.000 claims 1
• QEIDSSLUKKFBCE-UHFFFAOYSA-N methane;methanesulfonic acid Chemical class C.CS(O)(=O)=O QEIDSSLUKKFBCE-UHFFFAOYSA-N 0.000 claims 1
• 210000000653 nervous system Anatomy 0.000 claims 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
• WHYQCQRHPQBZHM-UHFFFAOYSA-N pyrazole-1-carboxylic acid Chemical compound OC(=O)N1C=CC=N1 WHYQCQRHPQBZHM-UHFFFAOYSA-N 0.000 claims 1
• 239000013557 residual solvent Substances 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 claims 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
• 150000007513 acids Chemical class 0.000 abstract description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 52
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
• 239000007787 solid Substances 0.000 description 38
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
• 108091007914 CDKs Proteins 0.000 description 37
• AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 37
• 108090000623 proteins and genes Proteins 0.000 description 37
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 35
• 239000012071 phase Substances 0.000 description 35
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 32
• 102000004169 proteins and genes Human genes 0.000 description 29
• 238000012360 testing method Methods 0.000 description 28
• 238000009472 formulation Methods 0.000 description 26
• 102000004190 Enzymes Human genes 0.000 description 25
• 108090000790 Enzymes Proteins 0.000 description 25
• 239000003795 chemical substances by application Substances 0.000 description 25
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
• 238000001802 infusion Methods 0.000 description 24
• 239000003112 inhibitor Substances 0.000 description 24
• UOTIBISWGOJBDS-UHFFFAOYSA-N hydrogen sulfate 1-methylpiperidin-1-ium Chemical compound OS([O-])(=O)=O.C[NH+]1CCCCC1 UOTIBISWGOJBDS-UHFFFAOYSA-N 0.000 description 23
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
• 229910052757 nitrogen Inorganic materials 0.000 description 20
• 239000000758 substrate Substances 0.000 description 20
• 241000196324 Embryophyta Species 0.000 description 19
• 238000001914 filtration Methods 0.000 description 19
• 229960000583 acetic acid Drugs 0.000 description 18
• 235000011054 acetic acid Nutrition 0.000 description 18
• 230000014509 gene expression Effects 0.000 description 17
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 230000005764 inhibitory process Effects 0.000 description 16
• 230000026731 phosphorylation Effects 0.000 description 16
• 238000006366 phosphorylation reaction Methods 0.000 description 16
• 230000001105 regulatory effect Effects 0.000 description 15
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
• 159000000021 acetate salts Chemical class 0.000 description 14
• 238000001990 intravenous administration Methods 0.000 description 14
• 239000011541 reaction mixture Substances 0.000 description 14
• 101150006300 CALCR gene Proteins 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 239000003085 diluting agent Substances 0.000 description 13
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
• 238000010521 absorption reaction Methods 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 230000022131 cell cycle Effects 0.000 description 12
• 239000000463 material Substances 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 206010017533 Fungal infection Diseases 0.000 description 11
• 208000031888 Mycoses Diseases 0.000 description 11
• 150000001412 amines Chemical class 0.000 description 11
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
• 239000004471 Glycine Substances 0.000 description 10
• 102000001253 Protein Kinase Human genes 0.000 description 10
• 229940121375 antifungal agent Drugs 0.000 description 10
• 230000008901 benefit Effects 0.000 description 10
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 10
• 235000019439 ethyl acetate Nutrition 0.000 description 10
• 239000007972 injectable composition Substances 0.000 description 10
• 150000002500 ions Chemical class 0.000 description 10
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 10
• 108060006633 protein kinase Proteins 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 238000004448 titration Methods 0.000 description 10
• 241000222122 Candida albicans Species 0.000 description 9
• 241000233866 Fungi Species 0.000 description 9
• 238000009835 boiling Methods 0.000 description 9
• 238000004108 freeze drying Methods 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 230000037361 pathway Effects 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 239000003755 preservative agent Substances 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 230000003827 upregulation Effects 0.000 description 9
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 239000003429 antifungal agent Substances 0.000 description 8
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 238000004587 chromatography analysis Methods 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 238000001035 drying Methods 0.000 description 8
• 229960000390 fludarabine Drugs 0.000 description 8
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 8
• 235000011187 glycerol Nutrition 0.000 description 8
• 239000012535 impurity Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
• 239000002502 liposome Substances 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 108020004999 messenger RNA Proteins 0.000 description 8
• 150000004702 methyl esters Chemical class 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 7
• 108010033040 Histones Proteins 0.000 description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• 235000015107 ale Nutrition 0.000 description 7
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 7
• 229950010817 alvocidib Drugs 0.000 description 7
• 230000000843 anti-fungal effect Effects 0.000 description 7
• 238000003782 apoptosis assay Methods 0.000 description 7
• 230000033228 biological regulation Effects 0.000 description 7
• 239000000460 chlorine Substances 0.000 description 7
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
• 239000011248 coating agent Substances 0.000 description 7
• 238000000576 coating method Methods 0.000 description 7
• 206010012601 diabetes mellitus Diseases 0.000 description 7
• 238000009396 hybridization Methods 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 239000008101 lactose Substances 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 208000015122 neurodegenerative disease Diseases 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 230000005522 programmed cell death Effects 0.000 description 7
• 150000003217 pyrazoles Chemical class 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 230000007704 transition Effects 0.000 description 7
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 6
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 6
• 102000038624 GSKs Human genes 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 229940095731 candida albicans Drugs 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 239000012141 concentrate Substances 0.000 description 6
• 239000008121 dextrose Substances 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 239000008187 granular material Substances 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 150000007523 nucleic acids Chemical class 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 238000001556 precipitation Methods 0.000 description 6
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 230000014616 translation Effects 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• YLSZRDSCDUGZOB-UHFFFAOYSA-N CS(=O)(=O)O.N1CCC(CC1)N Chemical compound CS(=O)(=O)O.N1CCC(CC1)N YLSZRDSCDUGZOB-UHFFFAOYSA-N 0.000 description 5
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
• 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 5
• 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 5
• 238000000354 decomposition reaction Methods 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 238000002405 diagnostic procedure Methods 0.000 description 5
• 238000010586 diagram Methods 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 239000002270 dispersing agent Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 230000002538 fungal effect Effects 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 238000002844 melting Methods 0.000 description 5
• 230000008018 melting Effects 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 102000039446 nucleic acids Human genes 0.000 description 5
• 108020004707 nucleic acids Proteins 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 238000001179 sorption measurement Methods 0.000 description 5
• 239000007921 spray Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000004094 surface-active agent Substances 0.000 description 5
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
• VRDBIJCCXDEZJN-UHFFFAOYSA-N 2-piperidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCCC1 VRDBIJCCXDEZJN-UHFFFAOYSA-N 0.000 description 4
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
• 241001225321 Aspergillus fumigatus Species 0.000 description 4
• 102000011727 Caspases Human genes 0.000 description 4
• 108010076667 Caspases Proteins 0.000 description 4
• 201000007336 Cryptococcosis Diseases 0.000 description 4
• 241000221204 Cryptococcus neoformans Species 0.000 description 4
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
• 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 4
• 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 4
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
• 238000004566 IR spectroscopy Methods 0.000 description 4
• 102000004877 Insulin Human genes 0.000 description 4
• 108090001061 Insulin Proteins 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 102400001093 PAK-2p27 Human genes 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 108091023040 Transcription factor Proteins 0.000 description 4
• 102000040945 Transcription factor Human genes 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• 229940091771 aspergillus fumigatus Drugs 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 238000006731 degradation reaction Methods 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 239000000417 fungicide Substances 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 229940125396 insulin Drugs 0.000 description 4
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• LRPCLTPZMUIPFK-UHFFFAOYSA-N methane;sulfuric acid Chemical class C.OS(O)(=O)=O LRPCLTPZMUIPFK-UHFFFAOYSA-N 0.000 description 4
• 208000005264 motor neuron disease Diseases 0.000 description 4
• 230000001537 neural effect Effects 0.000 description 4
• 230000004770 neurodegeneration Effects 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 235000011007 phosphoric acid Nutrition 0.000 description 4
• 239000008389 polyethoxylated castor oil Substances 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 230000009385 viral infection Effects 0.000 description 4
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 241000228197 Aspergillus flavus Species 0.000 description 3
• 206010007134 Candida infections Diseases 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 108090000257 Cyclin E Proteins 0.000 description 3
• 102000003909 Cyclin E Human genes 0.000 description 3
• 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 3
• 241000514744 Cyclina Species 0.000 description 3
• 229920000858 Cyclodextrin Polymers 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
• 239000000232 Lipid Bilayer Substances 0.000 description 3
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
• 102000043136 MAP kinase family Human genes 0.000 description 3
• 108091054455 MAP kinase family Proteins 0.000 description 3
• 239000007993 MOPS buffer Substances 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 240000003768 Solanum lycopersicum Species 0.000 description 3
• 206010048327 Supranuclear palsy Diseases 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 125000003118 aryl group Chemical group 0.000 description 3
• 230000008238 biochemical pathway Effects 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 210000000601 blood cell Anatomy 0.000 description 3
• 230000003139 buffering effect Effects 0.000 description 3
• 201000003984 candidiasis Diseases 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000001276 controlling effect Effects 0.000 description 3
• 239000010949 copper Substances 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 239000000645 desinfectant Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000004821 distillation Methods 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 206010015037 epilepsy Diseases 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 239000012456 homogeneous solution Substances 0.000 description 3
• 150000004677 hydrates Chemical class 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 3
• MCMHIMDGFPFWLT-UHFFFAOYSA-N methanesulfonic acid;n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound CS(O)(=O)=O.C1=CNN=C1C(=O)NC1CCNCC1 MCMHIMDGFPFWLT-UHFFFAOYSA-N 0.000 description 3
• ARAFBUCGMOKZMI-UHFFFAOYSA-N methyl 4-nitro-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1NN=CC=1[N+]([O-])=O ARAFBUCGMOKZMI-UHFFFAOYSA-N 0.000 description 3
• 230000000116 mitigating effect Effects 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 239000002105 nanoparticle Substances 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 230000003204 osmotic effect Effects 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000013618 particulate matter Substances 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 230000000865 phosphorylative effect Effects 0.000 description 3
• MXLUQLPDHXJJGL-UHFFFAOYSA-N piperidin-1-yl methanesulfonate Chemical compound CS(=O)(=O)ON1CCCCC1 MXLUQLPDHXJJGL-UHFFFAOYSA-N 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000002002 slurry Substances 0.000 description 3
• 239000001632 sodium acetate Substances 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000001384 succinic acid Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 239000002562 thickening agent Substances 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 102000007592 Apolipoproteins Human genes 0.000 description 2
• 108010071619 Apolipoproteins Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 201000002909 Aspergillosis Diseases 0.000 description 2
• 208000036641 Aspergillus infections Diseases 0.000 description 2
• 108700009171 B-Cell Lymphoma 3 Proteins 0.000 description 2
• 102000052666 B-Cell Lymphoma 3 Human genes 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 241000335423 Blastomyces Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 229940126074 CDK kinase inhibitor Drugs 0.000 description 2
• 241000222178 Candida tropicalis Species 0.000 description 2
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
• 108050007331 Cannabinoid receptor Proteins 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
• 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 2
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 241000228402 Histoplasma Species 0.000 description 2
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
• 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 102000003746 Insulin Receptor Human genes 0.000 description 2
• 108010001127 Insulin Receptor Proteins 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 101150096038 PTH1R gene Proteins 0.000 description 2
• 239000002033 PVDF binder Substances 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 240000005384 Rhizopus oryzae Species 0.000 description 2
• 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 241000255588 Tephritidae Species 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 241000209140 Triticum Species 0.000 description 2
• 235000021307 Triticum Nutrition 0.000 description 2
• 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
• 102000013814 Wnt Human genes 0.000 description 2
• 108050003627 Wnt Proteins 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 201000007691 actinomycosis Diseases 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 229940124650 anti-cancer therapies Drugs 0.000 description 2
• 239000012871 anti-fungal composition Substances 0.000 description 2
• 238000011319 anticancer therapy Methods 0.000 description 2
• 239000002111 antiemetic agent Substances 0.000 description 2
• 229940125683 antiemetic agent Drugs 0.000 description 2
• 239000011260 aqueous acid Substances 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• VQYOKDLEFVOVEV-UHFFFAOYSA-L bis(2,6-diphenylphenoxy)-methylalumane Chemical compound [Al+2]C.[O-]C1=C(C=2C=CC=CC=2)C=CC=C1C1=CC=CC=C1.[O-]C1=C(C=2C=CC=CC=2)C=CC=C1C1=CC=CC=C1 VQYOKDLEFVOVEV-UHFFFAOYSA-L 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 230000021164 cell adhesion Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 125000004803 chlorobenzyl group Chemical group 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 238000003869 coulometry Methods 0.000 description 2
• 150000001923 cyclic compounds Chemical class 0.000 description 2
• 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000030609 dephosphorylation Effects 0.000 description 2
• 238000006209 dephosphorylation reaction Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 229950006137 dexfosfoserine Drugs 0.000 description 2
• YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000011049 filling Methods 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000007710 freezing Methods 0.000 description 2
• 230000008014 freezing Effects 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 238000000227 grinding Methods 0.000 description 2
• 238000003898 horticulture Methods 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000003463 hyperproliferative effect Effects 0.000 description 2
• 229960004716 idoxuridine Drugs 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 229910052738 indium Inorganic materials 0.000 description 2
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 239000002917 insecticide Substances 0.000 description 2
• 230000006362 insulin response pathway Effects 0.000 description 2
• 239000011229 interlayer Substances 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 150000002739 metals Chemical class 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• LRMLHWFDAJXDMV-UHFFFAOYSA-N n,n-diethylethanamine;ethanamine Chemical compound CCN.CCN(CC)CC LRMLHWFDAJXDMV-UHFFFAOYSA-N 0.000 description 2
• 230000000626 neurodegenerative effect Effects 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 239000012457 nonaqueous media Substances 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• KKVUFSINQFSJNK-UHFFFAOYSA-N o-tert-butylhydroxylamine Chemical compound CC(C)(C)ON KKVUFSINQFSJNK-UHFFFAOYSA-N 0.000 description 2
• 238000005457 optimization Methods 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 229940127084 other anti-cancer agent Drugs 0.000 description 2
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
• 239000006174 pH buffer Substances 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• JLPGSSHHLKZYMJ-UHFFFAOYSA-N piperidin-4-amine;hydrochloride Chemical compound Cl.NC1CCNCC1 JLPGSSHHLKZYMJ-UHFFFAOYSA-N 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 238000004382 potting Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000031877 prophase Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000001243 protein synthesis Methods 0.000 description 2
• 238000010926 purge Methods 0.000 description 2
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000022983 regulation of cell cycle Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000002689 soil Substances 0.000 description 2
• 230000003381 solubilizing effect Effects 0.000 description 2
• 210000003802 sputum Anatomy 0.000 description 2
• 208000024794 sputum Diseases 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000005846 sugar alcohols Polymers 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 239000007916 tablet composition Substances 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 229940045860 white wax Drugs 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• PMRVNBLFPMPZHZ-WHDSNZPESA-N (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 PMRVNBLFPMPZHZ-WHDSNZPESA-N 0.000 description 1
• QHHHLHCCVDMOJI-UHFFFAOYSA-N 1,3-thiazol-4-amine Chemical class NC1=CSC=N1 QHHHLHCCVDMOJI-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• AIMFJYDQGGFYOE-UHFFFAOYSA-N 1-[(2,6-dichlorobenzoyl)amino]-n-piperidin-4-ylpyrazole-3-carboxamide Chemical group ClC1=CC=CC(Cl)=C1C(=O)NN1N=C(C(=O)NC2CCNCC2)C=C1 AIMFJYDQGGFYOE-UHFFFAOYSA-N 0.000 description 1
• QXHSVYRUQCTMQY-UHFFFAOYSA-N 1-[(2,6-dichlorobenzoyl)amino]pyrazole-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CN1NC(=O)C1=C(Cl)C=CC=C1Cl QXHSVYRUQCTMQY-UHFFFAOYSA-N 0.000 description 1
• CIQJWKNJDQKPPO-UHFFFAOYSA-N 1-chloropiperidine Chemical class ClN1CCCCC1 CIQJWKNJDQKPPO-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• GHFDYLOGYDGRHI-UHFFFAOYSA-N 1h-indeno[1,2-c]pyrazol-4-one Chemical class C12=CC=CC=C2C(=O)C2=C1NN=C2 GHFDYLOGYDGRHI-UHFFFAOYSA-N 0.000 description 1
• FTAYVIUSDFIIQI-UHFFFAOYSA-N 2,6-dichloro-n-(1h-pyrazol-4-yl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1 FTAYVIUSDFIIQI-UHFFFAOYSA-N 0.000 description 1
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
• YWACJRGCEVWOES-UHFFFAOYSA-N 2-aminoacetic acid methanesulfonic acid Chemical compound CS(O)(=O)=O.NCC(O)=O YWACJRGCEVWOES-UHFFFAOYSA-N 0.000 description 1
• JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
• ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
• SCHVGFGBJWBMFU-UHFFFAOYSA-N 3-sulfonylpyrazolo[3,4-b]pyridine Chemical class C1=CC=C2C(=S(=O)=O)N=NC2=N1 SCHVGFGBJWBMFU-UHFFFAOYSA-N 0.000 description 1
• UELIMKCXGLIYCY-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 UELIMKCXGLIYCY-UHFFFAOYSA-N 0.000 description 1
• NQNQKLBWDARKDG-UHFFFAOYSA-N 4-amino-1-piperidinecarboxylic acid Chemical compound NC1CCN(C(O)=O)CC1 NQNQKLBWDARKDG-UHFFFAOYSA-N 0.000 description 1
• SHRRRNSPESGSCM-UHFFFAOYSA-N 4-amino-1h-pyrazole-5-carboxylic acid Chemical compound NC1=CNN=C1C(O)=O SHRRRNSPESGSCM-UHFFFAOYSA-N 0.000 description 1
• JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
• FODMQPNJGQKTLS-UHFFFAOYSA-N 4-pyrazol-1-ylquinoline Chemical compound C1=CC=NN1C1=CC=NC2=CC=CC=C12 FODMQPNJGQKTLS-UHFFFAOYSA-N 0.000 description 1
• 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 1
• 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
• 108700001666 APC Genes Proteins 0.000 description 1
• 241000235389 Absidia Species 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
• 241001103582 Aelia Species 0.000 description 1
• 241001136792 Alle Species 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 241000351920 Aspergillus nidulans Species 0.000 description 1
• 241000228245 Aspergillus niger Species 0.000 description 1
• 241001465318 Aspergillus terreus Species 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 229930192334 Auxin Natural products 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
• 108060000903 Beta-catenin Proteins 0.000 description 1
• 102000015735 Beta-catenin Human genes 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010005098 Blastomycosis Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• QHLCMTIMVOHYCU-UHFFFAOYSA-N CC(O)=O.NC1CCNCC1 Chemical compound CC(O)=O.NC1CCNCC1 QHLCMTIMVOHYCU-UHFFFAOYSA-N 0.000 description 1
• 101150035324 CDK9 gene Proteins 0.000 description 1
• LSUWFNQQWUDHFK-UHFFFAOYSA-N COC1=CC=CC=C1.COC1=CC=CC=C1O Chemical class COC1=CC=CC=C1.COC1=CC=CC=C1O LSUWFNQQWUDHFK-UHFFFAOYSA-N 0.000 description 1
• 101100366714 Caenorhabditis elegans ssl-1 gene Proteins 0.000 description 1
• 241000189662 Calla Species 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
• 208000006029 Cardiomegaly Diseases 0.000 description 1
• 244000132059 Carica parviflora Species 0.000 description 1
• 235000014653 Carica parviflora Nutrition 0.000 description 1
• 101150053721 Cdk5 gene Proteins 0.000 description 1
• 101150090188 Cdk8 gene Proteins 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 229910002483 Cu Ka Inorganic materials 0.000 description 1
• 229910016523 CuKa Inorganic materials 0.000 description 1
• 108010025466 Cyclin-Dependent Kinase 3 Proteins 0.000 description 1
• 102100036871 Cyclin-J Human genes 0.000 description 1
• 102100021898 Cyclin-Q Human genes 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 102100021238 Dynamin-2 Human genes 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241001480035 Epidermophyton Species 0.000 description 1
• 241000221785 Erysiphales Species 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 102100031939 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
• MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000713131 Homo sapiens Cyclin-J Proteins 0.000 description 1
• 101000897452 Homo sapiens Cyclin-L2 Proteins 0.000 description 1
• 101000897449 Homo sapiens Cyclin-Q Proteins 0.000 description 1
• 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
• 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
• 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101100520968 Homo sapiens PPP1R1B gene Proteins 0.000 description 1
• 101000603402 Homo sapiens Protein NPAT Proteins 0.000 description 1
• 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010061217 Infestation Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• 150000000996 L-ascorbic acids Chemical class 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• 241000228456 Leptosphaeria Species 0.000 description 1
• 102220479923 Leucine-rich repeat-containing protein 26_H11A_mutation Human genes 0.000 description 1
• 241000234435 Lilium Species 0.000 description 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 241001480037 Microsporum Species 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 206010065764 Mucosal infection Diseases 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
• 101150067565 Nfatc1 gene Proteins 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 241000187654 Nocardia Species 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
• BHVRCUAHXVLSNX-UHFFFAOYSA-N O-[(4,5-dimethoxy-2-nitrophenyl)methyl]hydroxylamine Chemical compound COC1=CC(CON)=C([N+]([O-])=O)C=C1OC BHVRCUAHXVLSNX-UHFFFAOYSA-N 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 208000007027 Oral Candidiasis Diseases 0.000 description 1
• 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
• 241001537205 Paracoccidioides Species 0.000 description 1
• 241000736122 Parastagonospora nodorum Species 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010064458 Penicilliosis Diseases 0.000 description 1
• 241000228143 Penicillium Species 0.000 description 1
• 101800005149 Peptide B Proteins 0.000 description 1
• 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
• 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
• 108010001441 Phosphopeptides Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 241000233622 Phytophthora infestans Species 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
• 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 1
• 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 1
• 102100038870 Protein NPAT Human genes 0.000 description 1
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
• 101710149951 Protein Tat Proteins 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 102100024556 Protein phosphatase 1 regulatory subunit 1B Human genes 0.000 description 1
• 241000221300 Puccinia Species 0.000 description 1
• 241000540505 Puccinia dispersa f. sp. tritici Species 0.000 description 1
• 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038490 Renal pain Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 241000235525 Rhizomucor pusillus Species 0.000 description 1
• 101150112625 SSN3 gene Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 244000166071 Shorea robusta Species 0.000 description 1
• 235000015076 Shorea robusta Nutrition 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 206010041736 Sporotrichosis Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 102000050389 Syntaxin Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 241000223238 Trichophyton Species 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 241000287411 Turdidae Species 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 1
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000394605 Viola striata Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 230000004156 Wnt signaling pathway Effects 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241001360088 Zymoseptoria tritici Species 0.000 description 1
• DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• KMBSRIMRKLFIRP-UHFFFAOYSA-N acetic acid;4-[(2,6-dichlorobenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound CC(O)=O.ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 KMBSRIMRKLFIRP-UHFFFAOYSA-N 0.000 description 1
• MVFGXYPEQHIKIX-UHFFFAOYSA-N acetic acid;heptane Chemical class CC(O)=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-N 0.000 description 1
• WLZISOTZQFNGGL-UHFFFAOYSA-N acetic acid;n-piperidin-4-yl-1h-pyrazole-5-carboxamide Chemical compound CC(O)=O.C=1C=NNC=1C(=O)NC1CCNCC1 WLZISOTZQFNGGL-UHFFFAOYSA-N 0.000 description 1
• 150000001243 acetic acids Chemical class 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 150000008043 acidic salts Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 238000002159 adsorption--desorption isotherm Methods 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000003349 alamar blue assay Methods 0.000 description 1
• 208000028505 alcohol-related disease Diseases 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 239000004411 aluminium Substances 0.000 description 1
• 125000006242 amine protecting group Chemical group 0.000 description 1
• UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000012296 anti-solvent Substances 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940125687 antiparasitic agent Drugs 0.000 description 1
• 239000003096 antiparasitic agent Substances 0.000 description 1
• 229910000266 aqualite Inorganic materials 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 239000002363 auxin Substances 0.000 description 1
• JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
• IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 150000001555 benzenes Chemical class 0.000 description 1
• WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 238000012925 biological evaluation Methods 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 238000002815 broth microdilution Methods 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• OVYQSRKFHNKIBM-UHFFFAOYSA-N butanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O OVYQSRKFHNKIBM-UHFFFAOYSA-N 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 238000007707 calorimetry Methods 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 239000007963 capsule composition Substances 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 235000019994 cava Nutrition 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 238000002701 cell growth assay Methods 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 229920006184 cellulose methylcellulose Polymers 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
• 239000003610 charcoal Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000010668 complexation reaction Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 208000013044 corticobasal degeneration disease Diseases 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
• 238000010908 decantation Methods 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 239000002837 defoliant Substances 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
• 238000007598 dipping method Methods 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
• 239000004491 dispersible concentrate Substances 0.000 description 1
• KAXCBTXPUVEMDP-UHFFFAOYSA-N dithiocyanatophosphoryl thiocyanate Chemical compound N#CSP(=O)(SC#N)SC#N KAXCBTXPUVEMDP-UHFFFAOYSA-N 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• 201000005619 esophageal carcinoma Diseases 0.000 description 1
• YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• PESLMYOAEOTLFJ-UHFFFAOYSA-N ethoxymethylsilane Chemical compound CCOC[SiH3] PESLMYOAEOTLFJ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 239000006052 feed supplement Substances 0.000 description 1
• 239000003337 fertilizer Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 229960004884 fluconazole Drugs 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• 230000000855 fungicidal effect Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000001879 gelation Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 230000000749 insecticidal effect Effects 0.000 description 1
• 239000013461 intermediate chemical Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 238000012792 lyophilization process Methods 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 208000004396 mastitis Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
• QLYCZINKZANMRY-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O.CS(O)(=O)=O QLYCZINKZANMRY-UHFFFAOYSA-N 0.000 description 1
• ORUCTBNNYKZMSK-UHFFFAOYSA-N methyl 1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1C=CNN=1 ORUCTBNNYKZMSK-UHFFFAOYSA-N 0.000 description 1
• HLYXFFRYNIEWHO-UHFFFAOYSA-N methyl 4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl HLYXFFRYNIEWHO-UHFFFAOYSA-N 0.000 description 1
• IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
• MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
• 231100000782 microtubule inhibitor Toxicity 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• IDSXLJLXYMLSJM-UHFFFAOYSA-N morpholine;propane-1-sulfonic acid Chemical compound C1COCCN1.CCCS(O)(=O)=O IDSXLJLXYMLSJM-UHFFFAOYSA-N 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 238000000491 multivariate analysis Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• GGGWEBORYHXRBM-UHFFFAOYSA-N n,n-dimethylacetamide;pyrrolidin-2-one Chemical compound CN(C)C(C)=O.O=C1CCCN1 GGGWEBORYHXRBM-UHFFFAOYSA-N 0.000 description 1
• WMSQJZHVGMMPQT-UHFFFAOYSA-N n-chlorobenzamide Chemical compound ClNC(=O)C1=CC=CC=C1 WMSQJZHVGMMPQT-UHFFFAOYSA-N 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• LUHFJLLCZSYACL-UHFFFAOYSA-N o-(2,2,2-trichloroethyl)hydroxylamine Chemical compound NOCC(Cl)(Cl)Cl LUHFJLLCZSYACL-UHFFFAOYSA-N 0.000 description 1
• GWCBVFMHGHMALR-UHFFFAOYSA-N o-(2-trimethylsilylethyl)hydroxylamine Chemical compound C[Si](C)(C)CCON GWCBVFMHGHMALR-UHFFFAOYSA-N 0.000 description 1
• XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
• OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000008203 oral pharmaceutical composition Substances 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000003415 peat Substances 0.000 description 1
• 150000004965 peroxy acids Chemical class 0.000 description 1
• 239000003186 pharmaceutical solution Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• UNQNIRQQBJCMQR-UHFFFAOYSA-N phosphorine Chemical compound C1=CC=PC=C1 UNQNIRQQBJCMQR-UHFFFAOYSA-N 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• VPBCWHDJJAEBGL-UHFFFAOYSA-N piperidin-1-ium-1-sulfonate Chemical compound OS(=O)(=O)N1CCCCC1 VPBCWHDJJAEBGL-UHFFFAOYSA-N 0.000 description 1
• SGQDWDWJCYEUNC-UHFFFAOYSA-N piperidin-1-ium-4-ylazanium;dichloride Chemical compound Cl.Cl.NC1CCNCC1 SGQDWDWJCYEUNC-UHFFFAOYSA-N 0.000 description 1
• HAGVWBQWCRHRRA-UHFFFAOYSA-N piperidin-1-yl acetate Chemical compound CC(=O)ON1CCCCC1 HAGVWBQWCRHRRA-UHFFFAOYSA-N 0.000 description 1
• KXBFBEFVLGTPBO-UHFFFAOYSA-N piperidin-1-yl hydrogen sulfate Chemical compound OS(=O)(=O)ON1CCCCC1 KXBFBEFVLGTPBO-UHFFFAOYSA-N 0.000 description 1
• XPZWNIXACVBLAK-UHFFFAOYSA-N piperidin-1-ylmethanesulfonic acid Chemical compound OS(=O)(=O)CN1CCCCC1 XPZWNIXACVBLAK-UHFFFAOYSA-N 0.000 description 1
• 239000003880 polar aprotic solvent Substances 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical group CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000025915 regulation of apoptotic process Effects 0.000 description 1
• 230000031539 regulation of cell division Effects 0.000 description 1
• 230000029892 regulation of protein phosphorylation Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 239000005871 repellent Substances 0.000 description 1
• 230000002940 repellent Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000028617 response to DNA damage stimulus Effects 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 238000002390 rotary evaporation Methods 0.000 description 1
• 239000012449 sabouraud dextrose agar Substances 0.000 description 1
• 239000004576 sand Substances 0.000 description 1
• 238000000646 scanning calorimetry Methods 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000004296 sodium metabisulphite Substances 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• RHZZMUCBMSWAHK-UAIGNFCESA-M sodium;(z)-but-2-enedioic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)\C=C/C(O)=O RHZZMUCBMSWAHK-UAIGNFCESA-M 0.000 description 1
• IGHGOYDCVRUTSU-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O IGHGOYDCVRUTSU-UHFFFAOYSA-M 0.000 description 1
• POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
• XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000011973 solid acid Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 238000013112 stability test Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 108020001568 subdomains Proteins 0.000 description 1
• 239000002352 surface water Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
• YPSOVQYHIDHKDO-UHFFFAOYSA-N tert-butyl 4-[[4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carbonyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl YPSOVQYHIDHKDO-UHFFFAOYSA-N 0.000 description 1
• LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
• RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• BHAROVLESINHSM-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1.CC1=CC=CC=C1 BHAROVLESINHSM-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• CUOOSKOJMQOZCM-UHFFFAOYSA-H tricalcium carbonic acid diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].C(O)(O)=O.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] CUOOSKOJMQOZCM-UHFFFAOYSA-H 0.000 description 1
• JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 150000003668 tyrosines Chemical class 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 238000007473 univariate analysis Methods 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000003828 vacuum filtration Methods 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• 239000002966 varnish Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000009941 weaving Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 201000008552 xeroderma pigmentosum group A Diseases 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 1